GPX4 and hepatocellular carcinoma: Moreover, we found that the expression of GPX4 and DHODH was upregulated in sorafenib-resistant patients (Figures 2A, B) and associated with poor prognosis of HCC patients who received sorafenib treatment (Figures 2C, D).